Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation

被引:78
|
作者
Chan, C. Stanley [1 ]
Van Voorhees, Abby S. [2 ]
Lebwohl, Mark G. [3 ]
Korman, Neil J. [5 ,6 ]
Young, Melodic
Bebo, Bruce F., Jr.
Kalb, Robert E. [4 ]
Hsu, Sylvia [1 ]
机构
[1] Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] SUNY Buffalo, Sch Med, Buffalo, NY 14260 USA
[5] Case Western Reserve Univ, Univ Hosp Cleveland, Dept Dermatol, Cleveland, OH 44106 USA
[6] Case Western Reserve Univ, Univ Hosp Cleveland, Murdough Family Ctr Psoriasis, Cleveland, OH 44106 USA
关键词
CLOBETASOL PROPIONATE FOAM; TAZAROTENE 0.1-PERCENT GEL; PLAQUE PSORIASIS; CALCIPOTRIOL SOLUTION; BETAMETHASONE; 17-VALERATE; DOVOBET(R) OINTMENT; CLINICAL-EVALUATION; DOUBLE-BLIND; COAL-TAR; EFFICACY;
D O I
10.1016/j.jaad.2008.11.890
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background The scalp is the most commonly affected part of the body in patients with psoriasis. Signs and symptoms of scalp psoriasis vary significantly for individual patients. Objective. A task force of the National Psoriasis Foundation was convened to evaluate treatment options. Our aim was to achieve a consensus for scalp psoriasis therapy. Methods: Reports in the medical literature were reviewed regarding scalp psoriasis therapy. Limitations: There is a paucity of evidence-based and double-blind Studies in the treatment of scalp psoriasis particularly for long-term therapy. Many of the studies in scalp psoriasis were designed to attain Food and Drug Administration approval for a medication and not to provide treatment guidance. Conclusions: The recommended short-term or intermittent therapy for scalp psoriasis is topical corticosteroids. The primary alternatives are topical retinoids, vitamin D analogues, and salicylic acid. Combination therapy has many advantages. The choice of an appropriate vehicle is crucial to increase patient compliance. While scalp psoriasis can often be adequately treated With topical therapy, recalcitrant disease may require more aggressive approaches, including systemic agents. (J Am Acad Dermatol 2009;60:962-71.)
引用
收藏
页码:962 / 971
页数:10
相关论文
共 50 条
  • [21] Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy
    Elmets, Craig A.
    Lim, Henry W.
    Stoff, Benjamin
    Connor, Cody
    Cordoro, Kelly M.
    Lebwohl, Mark
    Armstrong, April W.
    Davis, Dawn M. R.
    Elewski, Boni E.
    Gelfand, Joel M.
    Gordon, Kenneth B.
    Gottlieb, Alice B.
    Kaplan, Daniel H.
    Kavanaugh, Arthur
    Kiselica, Matthew
    Kivelevitch, Dario
    Korman, Neil J.
    Kroshinsky, Daniela
    Leonardi, Craig L.
    Lichten, Jason
    Mehta, Nehal N.
    Paller, Amy S.
    Parra, Sylvia L.
    Pathy, Arun L.
    Prater, Elizabeth A. Farley
    Rupani, Reena N.
    Siegel, Michael
    Strober, Bruce E.
    Wong, Emily B.
    Wu, Jashin J.
    Hariharan, Vidhya
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (03) : 775 - 804
  • [22] Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis
    Radtke, M. A.
    Herberger, K.
    Kornek, T.
    Augustin, M.
    HAUTARZT, 2010, 61 (09): : 770 - 775
  • [23] INFLIXIMAB BIOSIMILAR VERSUS METHOTREXATE FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS
    Sarbu, Maria-Isabela
    Tampa, Mircea
    Matei, Clara
    Mitran, Cristina-Iulia
    Mitran, Madalina-Irina
    Pituru, Silviu
    Pop, Corina Silvia
    Saramet, Gabriel
    Georgescu, Simona-Roxana
    FARMACIA, 2017, 65 (06) : 962 - 967
  • [24] The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry
    Merola, J. F.
    Chada, L. M. Perez
    Siegel, M.
    Bagel, J.
    Evans, C.
    Lockshin, B.
    Mason, M.
    Guo, N.
    McLean, R. R.
    Greenberg, J. D.
    Van Voorhees, A. S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (09) : 2051 - 2058
  • [25] Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis
    Li, Wendy
    Ghamrawi, Rima
    Haidari, Wasim
    Feldman, Steven R.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (04) : 380 - 387
  • [26] Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
    Kivelevitch, Dario
    Amin, Sima
    Menter, Alan
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2019, 12 : 249 - 253
  • [27] Acitretin for the Treatment of Psoriasis: An Assessment of National Trends
    Ghasri, Pedram
    Yentzer, Brad A.
    Dabade, Tushar S.
    Feldman, Steven R.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2011, 10 (08) : 873 - 877
  • [28] The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis - an introduction
    Freeman, Keith
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (01) : 197 - 203
  • [29] Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study
    Rompoti, Natalia
    Katsimbri, Pelagia
    Kokkalis, Georgios
    Boumpas, Dimitrios
    Ikonomidis, Ignatios
    Theodoropoulos, Konstantinos
    Rigopoulos, Dimitris
    Papadavid, Evangelia
    DERMATOLOGIC THERAPY, 2019, 32 (05)
  • [30] Ustekinumab Induces Fast Response and Maintenance of Very Severe Refractory Scalp Psoriasis: Results in Two Greek Patients from the Psoriasis Hospital-Based Clinic
    Papadavid, E.
    Ferra, D.
    Koumaki, D.
    Dalamaga, M.
    Stamou, C.
    Theodoropoulos, K.
    Rigopoulos, D.
    DERMATOLOGY, 2014, 228 (02) : 107 - 111